Modality
Fusion Protein
MOA
C5i
Target
CD38
Pathway
Hedgehog
EpilepsyCrohn's
Development Pipeline
Preclinical
~Jun 2014
→ ~Sep 2015
Phase 1
~Dec 2015
→ ~Mar 2017
Phase 2
~Jun 2017
→ ~Sep 2018
Phase 3
~Dec 2018
→ ~Mar 2020
NDA/BLA
Jun 2020
→ Nov 2027
NDA/BLACurrent
NCT03891122
150 pts·Epilepsy
2020-06→2027-11·Terminated
150 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-181.6y awayPh3 Readout· Epilepsy
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2027-11-18 · 1.6y away
Epilepsy
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03891122 | NDA/BLA | Epilepsy | Terminated | 150 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 |